{Reference Type}: Journal Article
{Title}: Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy.
{Author}: Tang L;Luo Y;Luo W;Sun G;Jiang Y;Zhang Z;Yue X;Li S;Liang L;Liu W;Hu J;
{Journal}: Curr Protein Pept Sci
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 25
{Factor}: 3.118
{DOI}: 10.2174/0113892037297416240525155628
{Abstract}: Platinum (II) drugs, including cisplatin, carboplatin, and oxaliplatin, have achieved significant clinical success in cancer treatment. However, their clinical application has been greatly hindered by various adverse factors such as non-specific activation and drug resistance. Compared with Pt(II) drugs, the axial ligands within Pt(IV) compounds can improve the pharmacokinetic properties, selectivity, and biological activity, implementing alternative cytotoxic mechanisms beyond DNA cross-linking and partially overcoming drug resistance. The controlled conversion of Pt(IV) prodrugs into Pt(II) agents at the tumor site has been extensively explored internationally. In this review, Pt(IV) prodrug modification strategies are first summarized, next the development of the predominant external and internal photosensitizers is listed. Finally, three representative photoreduction mechanisms and strategies for developing corresponding Pt(IV) prodrugs are discussed. This work provides constructive instruction for the subsequent molecular design of Pt(IV) prodrugs. </p>.